{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:29:19Z","timestamp":1782019759566,"version":"3.54.5"},"reference-count":426,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dld.2025.10.025","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:27:53Z","timestamp":1762878473000},"page":"2257-2278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Societ\u00e0 Italiana di Reumatologia (SIR), Societ\u00e0 Italiana Trapianti d'Organo (SITO), Societ\u00e0 Italiana di Gastroenterologia (SIGE), Societ\u00e0 Italiana di Malattie Infettive e Tropicali (SIMIT)"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-1767","authenticated-orcid":false,"given":"Mauro","family":"Vigan\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Celsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9452-5489","authenticated-orcid":false,"given":"Agostino","family":"Colli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-3156","authenticated-orcid":false,"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"D\u2019Offizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8308-0701","authenticated-orcid":false,"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gambato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Girmenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lauterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-9289","authenticated-orcid":false,"given":"Marcello","family":"Maida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6466-1412","authenticated-orcid":false,"given":"Nicola","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2566-3041","authenticated-orcid":false,"given":"Pierluigi","family":"Toniutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Calvaruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.10.025_bib0001","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"25","key":"10.1016\/j.dld.2025.10.025_bib0002","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"S0168-8278","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0003","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis b virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0004","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","article-title":"Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion","volume":"77","author":"Papatheodoridis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0005","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/jvh.13248","article-title":"An estimation of the prevalence of occult HBV infection in Western Europe and in Northern America: a meta-analysis","volume":"27","author":"Pisaturo","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0006","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2174\/0115680266292661240322072908","article-title":"Approaches towards better immunosuppressive agents","volume":"24","author":"Walczak","year":"2024","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.dld.2025.10.025_bib0007","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2025.10.025_bib0008","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00277-004-0899-y","article-title":"Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP","volume":"83","author":"Dai","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0009","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin\u2019s lymphoma: a randomized trial","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0010","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0011","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3109\/10428194.2013.813502","article-title":"Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance","volume":"55","author":"Chew","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0012","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.3748\/wjg.v25.i26.3299","article-title":"Reactivation of hepatitis B virus infection in patients with hemolymphoproliferative diseases, and its prevention","volume":"25","author":"Sagnelli","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0013","doi-asserted-by":"crossref","first-page":"14581","DOI":"10.3748\/wjg.v20.i40.14581","article-title":"Chemotherapy-related reactivation of Hepatitis B infection: updates in 2013","volume":"20","author":"Kim","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0014","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol"},{"issue":"5 Suppl","key":"10.1016\/j.dld.2025.10.025_bib0015","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","article-title":"Prophylaxis and treatment of hepatitis B in immunocompromised patients","volume":"39","author":"Marzano","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0017","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cgh.2009.06.027","article-title":"Reactivation of Hepatitis B with reappearance of Hepatitis B surface antigen after chemotherapy and immune suppression","volume":"7","author":"Palmore","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0019","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.10.025_bib0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3324\/haematol.2018.210252","article-title":"Reactivation of hepatitis B virus infection in patients with hematologic disorders","volume":"104","author":"Wang","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.dld.2025.10.025_bib0021","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on Hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?","volume":"61","author":"Di Bisceglie","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0022","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0023","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.10.025_bib0024","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of Hepatitis B virus reactivation in At-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.10.025_bib0025","unstructured":"https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale"},{"key":"10.1016\/j.dld.2025.10.025_bib0026","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/gut.2005.070763","article-title":"Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy","volume":"54","author":"Hui","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.dld.2025.10.025_bib0027","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/cid\/civ344","article-title":"Monitoring of Hepatitis B Virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study","volume":"61","author":"Kusumoto","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0028","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0029","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1111\/liv.16064","article-title":"What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis","volume":"44","author":"Celsa","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0030","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1186\/s12885-015-2033-z","article-title":"Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors","volume":"15","author":"Brasseur","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0031","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","article-title":"Prevalence of Hepatitis B virus, Hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices","volume":"5","author":"Ramsey","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0032","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/JCO.2017.75.6387","article-title":"Models to predict Hepatitis B virus infection among patients with cancer undergoing systemic anticancer therapy: a prospective cohort study","volume":"36","author":"Hwang","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0033","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/ard.2005.043257","article-title":"Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies","volume":"65","author":"Calabrese","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0034","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrrheum.2012.63","article-title":"Management of rheumatic disease with comorbid HBV or HCV infection","volume":"8","author":"Vassilopoulos","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002726","article-title":"Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"8","author":"Fragoulis","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.dld.2025.10.025_bib0036","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.dld.2025.10.025_bib0038","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.vaccine.2017.03.080","article-title":"Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"35","author":"Jiang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.dld.2025.10.025_bib0039","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.10.025_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00097","article-title":"Cost-effectiveness analysis of Hepatitis B virus screening and management in patients with hematologic or solid malignancies anticipating immunosuppressive cancer therapy","volume":"3","author":"Hwang","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.dld.2025.10.025_bib0041","doi-asserted-by":"crossref","first-page":"619","DOI":"10.17235\/reed.2017.4693\/2016","article-title":"Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms","volume":"109","author":"Crespo","year":"2017","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.dld.2025.10.025_bib0042","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2011.40.7510","article-title":"Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis","volume":"30","author":"Zurawska","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0043","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-015-3382-7","article-title":"Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis","volume":"151","author":"Wong","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.dld.2025.10.025_bib0044","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.cgh.2019.10.039","article-title":"Cost-effectiveness analysis of screening for Hepatitis B virus infection in patients with solid tumors before initiating chemotherapy","volume":"18","author":"Konijeti","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0045","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JGO.2015.001669","article-title":"Cost effectiveness of universal Hepatitis B virus screening in patients beginning chemotherapy for Sarcomas or GI stromal tumors","volume":"2","author":"Tan","year":"2016","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0046","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2011.35.1635","article-title":"Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors","volume":"29","author":"Day","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0047","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0048","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","article-title":"Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"15","author":"Yeo","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0049","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14712598.2016.1177017","article-title":"Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders","volume":"16","author":"Vigan\u00f2","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.10.025_bib0051","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.29082","article-title":"Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis","volume":"66","author":"Paul","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0052","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jfma.2019.05.027","article-title":"Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection","volume":"119","author":"Tsou","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.dld.2025.10.025_bib0053","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00277-012-1405-6","article-title":"Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy","volume":"91","author":"Pei","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0054","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12185-015-1750-z","article-title":"Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy","volume":"101","author":"Totani","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0055","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.bbmt.2008.08.007","article-title":"HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection","volume":"14","author":"Onozawa","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0056","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2009.05.001","article-title":"Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hammond","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0057","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","article-title":"Moderate risk of Hepatitis B Virus reactivation in HBsAg(-)\/HBcAb(+) carriers receiving Rituximab for rheumatoid arthritis","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.dld.2025.10.025_bib0058","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/1756-185X.13401","article-title":"Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"22","author":"Watanabe","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0059","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/1756-185X.13582","article-title":"Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: a long-term, real-world observation","volume":"22","author":"Chen","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0060","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3899\/jrheum.110289","article-title":"Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases","volume":"38","author":"Kato","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0061","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2021-220774","article-title":"Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease","volume":"80","author":"Chen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0062","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13075-018-1748-z","article-title":"Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study","volume":"20","author":"Tien","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0063","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/v14071504","article-title":"Occult Hepatitis B virus infection: an update","volume":"14","author":"Saitta","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.dld.2025.10.025_bib0064","first-page":"480","article-title":"Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review","volume":"31","author":"Cholongitas","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/liv.13953","article-title":"Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B","volume":"39","author":"Wong","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0066","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1440-1843.2010.01798.x","article-title":"Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids","volume":"15","author":"Kim","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.dld.2025.10.025_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfma.2017.07.004","article-title":"Hepatitis B virus-related mortality in rheumatoid arthritis patients undergoing long-term low-dose glucocorticoid treatment: a population-based study","volume":"117","author":"Yang","year":"2018","journal-title":"J Formosan Med Assoc"},{"key":"10.1016\/j.dld.2025.10.025_bib0068","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0069","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/cam4.2868","article-title":"PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence","volume":"9","author":"Byeon","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.05.020","article-title":"Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: experience from a single Asian centre","volume":"146","author":"Chan","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0071","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1111\/ajco.13454","article-title":"Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: experience of a tertiary Asian Center","volume":"17","author":"Ng","year":"2021","journal-title":"Asia-Pac J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0072","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0073","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2020.02.013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with nonsmall cell lung cancer and hepatitis B or hepatitis C infection","volume":"145","author":"Pertejo-Fernandez","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0074","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.14309\/ajg.0000000000001142","article-title":"Hepatitis flare during immunotherapy in patients with current or past hepatitis B virus infection","volume":"116","author":"Wong","year":"2021","journal-title":"Am J Gastro"},{"key":"10.1016\/j.dld.2025.10.025_bib0075","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cgh.2021.06.019","article-title":"Risk of Hepatitis B virus reactivation in patients TreatedWith immunotherapy for anti-cancer treatment","volume":"20","author":"Yoo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0076","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0077","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211031141","article-title":"Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab","volume":"13","author":"Hsu","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0078","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0079","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CMR.0000000000000256","article-title":"Safety of immune checkpoint inhibitors in Chinese patients with melanoma","volume":"26","author":"Wen","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000434","article-title":"Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series","volume":"28","author":"Kothapalli","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0081","first-page":"247","article-title":"Hepatitis B reactivation rate is higher undergoing some cytotoxic chemotherapy in patients with solid tumors: a large retrospective study","volume":"63","author":"Karaca","year":"2018","journal-title":"Chemotherapy (Los Angel)"},{"key":"10.1016\/j.dld.2025.10.025_bib0082","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3904\/kjim.2007.22.4.237","article-title":"Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience","volume":"22","author":"Kim","year":"2007","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0083","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/14712598.2012.646986","article-title":"Anti-TNF drugs in patients with Hepatitis B or C virus infection: safety and clinical management","volume":"12","author":"Vigano\u2019","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0084","article-title":"HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-\u03b1) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","volume":"2014","author":"Cantini","year":"2014","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0085","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0086","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10067-013-2385-1","article-title":"Anti-TNF therapy in patients with HBV infection- analysis of 87 patients with inflammatory arthritis","volume":"33","author":"Ye","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0087","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3899\/jrheum.081324","article-title":"Reactivation of Hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor alpha therapy","volume":"36","author":"Chung","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0088","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0089","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatininb inhibits T-cell-receptor mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.10.025_bib0090","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.leu.2403401","article-title":"Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro","volume":"18","author":"Cwynarski","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.dld.2025.10.025_bib0091","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1080\/10428194.2016.1260127","article-title":"Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia","volume":"58","author":"Orlandi","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0092","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2019.05.001","article-title":"Hepatitis B reactivation during treatment of tyrosine kinase inhibitors-experience in 142 adult patients with chronic myeloid leukemia","volume":"81","author":"Wang","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0093","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.05.032","article-title":"Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non\u2013small-cell lung cancer patients","volume":"117","author":"Yao","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0094","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jgh.12898","article-title":"Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib","volume":"30","author":"Lim","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0095","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3109\/10428194.2014.941833","article-title":"Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant","volume":"56","author":"Li","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0096","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/annonc\/mdr142","article-title":"Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection","volume":"23","author":"Mya","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0097","first-page":"266","article-title":"Hepatitis B reactivation rate and fate among Multiple Myeloma patients receiving regimens containing lenalidomide and\/or Bortezomib","volume":"36","author":"Ataca Atilla","year":"2019","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0098","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/0366-6999.174508","article-title":"Efficacy and safety of Bortezomib in Multiple Myeloma patients with Hepatitis B: a multicenter retrospective study","volume":"129","author":"Lu","year":"2016","journal-title":"Chin Med J"},{"key":"10.1016\/j.dld.2025.10.025_bib0099","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of Hepatitis B reactivation in patients with psoriasis on Ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.dld.2025.10.025_bib0100","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0101","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of Secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.dld.2025.10.025_bib0102","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s10620-020-06725-1","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab-containing treatment","volume":"66","author":"Kuo","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2025.10.025_bib0103","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0104","doi-asserted-by":"crossref","first-page":"SI252","DOI":"10.1093\/rheumatology\/kead243","article-title":"HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis","volume":"62","author":"Katelani","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0105","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/1756-185X.14217","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib","volume":"24","author":"Wang","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0106","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/acr.21654","article-title":"Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jmii.2017.04.002","article-title":"Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis \u2013 a three-year study in Taiwan","volume":"52","author":"Lin","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.dld.2025.10.025_bib0108","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/acr.22786","article-title":"Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present Hepatitis B virus infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0109","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s13555-022-00682-5","article-title":"Risk for Hepatitis B Virus reactivation in patients with psoriasis treated with biological agents: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0110","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/apt.17155","article-title":"Meta-analysis: hepatitis B reactivation in patients receiving biological therapy","volume":"56","author":"El Jamaly","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0111","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/14712598.2014.912273","article-title":"Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy","volume":"14","author":"Vigan\u00f2","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0112","first-page":"1229","article-title":"Combined treatment with anti CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas","volume":"87","author":"Domingo-Domenech","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.dld.2025.10.025_bib0113","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1034\/j.1600-0609.2002.01692.x","article-title":"Rituximab (anti-CD20 monoclonal antibody) as consolidation of first line CHOP chemotherapy in patients with follicular lymphoma: a phase II study","volume":"69","author":"Jaeger","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0114","article-title":"Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab","volume":"88","author":"Hernandez","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.dld.2025.10.025_bib0115","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/1042819031000151923","article-title":"Hepatitis B virus reactivation in a case of Non-Hodgkin\u2019s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy","volume":"45","author":"Tsutsumi","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0116","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001813-200501000-00012","article-title":"Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab","volume":"16","author":"Zell","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.dld.2025.10.025_bib0117","doi-asserted-by":"crossref","first-page":"a423","DOI":"10.1136\/bmj.39490.680498.BE","article-title":"Fatal reactivation of hepatitis B after chemotherapy for lymphoma","volume":"337","author":"Dillon","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2025.10.025_bib0118","first-page":"483","article-title":"Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine cyclophosphamide rituximab for low grade non hodgkin\u2019s lymphoma","volume":"13","author":"Wasmuth","year":"2008","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0119","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/030089160809400519","article-title":"Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin's lymphoma","volume":"94","author":"Marino","year":"2008","journal-title":"Tumori"},{"key":"10.1016\/j.dld.2025.10.025_bib0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12185-009-0359-5","article-title":"Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma","volume":"90","author":"Kusumoto","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0121","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00431-009-1000-6","article-title":"Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier","volume":"169","author":"Aomatsu","year":"2010","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.dld.2025.10.025_bib0122","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3851\/IMP1633","article-title":"Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen","volume":"15","author":"Rago","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0123","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0028-1109782","article-title":"Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab","volume":"48","author":"Stange","year":"2010","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0124","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1634\/theoncologist.2010-0182","article-title":"An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening","volume":"16","author":"Leung","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.dld.2025.10.025_bib0125","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1016\/j.transproceed.2013.03.047","article-title":"Urgent liver transplantation for chemotherapy-induced HBV reactivation: a suitable option in patients recently treated for malignant lymphoma","volume":"45","author":"Sperl","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2025.10.025_bib0126","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3350\/cmh.2013.19.1.51","article-title":"A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience","volume":"19","author":"Oh","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0127","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00277-007-0396-1","article-title":"Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma","volume":"87","author":"Yang","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0128","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2133.2006.07451.x","article-title":"Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma","volume":"155","author":"Perceau","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajh.21343","article-title":"Incidence of hepatitis B reactivation following Rituximab therapy","volume":"84","author":"Hanbali","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00277-008-0585-6","article-title":"Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin\u2019s lymphoma in Hokkaido","volume":"88","author":"Tsutsumi","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0131","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1478-3231.2010.02332.x","article-title":"Hepatitis B screening, prophylaxis and reactivation in the era of rituximab-based chemotherapy","volume":"31","author":"Mendez-Navarro","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0132","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s12032-011-9974-0","article-title":"The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy","volume":"29","author":"Chen","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0133","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","article-title":"Risk of hepatitis B virus (HBV) reactivation in non-hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis","volume":"57","author":"Dong","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.dld.2025.10.025_bib0134","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2022.11.024","article-title":"Patients treated with rituximab are poorly screened for hepatitis B infection: data from a low-incidence country","volume":"108","author":"Brakenhoff","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0135","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bjh.17142","article-title":"Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study","volume":"192","author":"Huang","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0136","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/cas.14846","article-title":"Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy","volume":"112","author":"Yamauchi","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.dld.2025.10.025_bib0137","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","article-title":"Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients","volume":"89","author":"Pei","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0138","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1038\/s41375-020-0913-y","article-title":"Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection","volume":"34","author":"Yang","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.dld.2025.10.025_bib0139","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3109\/10428194.2012.659735","article-title":"Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group","volume":"53","author":"Kim","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0140","doi-asserted-by":"crossref","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0141","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0142","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0143","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0144","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0145","article-title":"Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: a three-year observational cohort study","volume":"8","author":"Zingaropoli","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.dld.2025.10.025_bib0146","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"FDA: increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2025.10.025_bib0147","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1093\/cid\/ciab302","article-title":"Reactivation of resolved hepatitis B after daratumumab for multiple myeloma","volume":"73","author":"Lee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0148","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1007\/s11096-023-01608-7","article-title":"Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis","volume":"45","author":"Moore","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.dld.2025.10.025_bib0149","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2020004907","article-title":"Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR Tcell therapy","volume":"136","author":"Cao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.10.025_bib0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hon.2807","article-title":"Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection","volume":"39","author":"Cui","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0151","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjh.16951","article-title":"Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy","volume":"191","author":"Liu","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0152","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1038\/s41375-020-0936-4","article-title":"Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection","volume":"34","author":"Wang","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.dld.2025.10.025_bib0153","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41409-023-01960-2","article-title":"HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy","volume":"58","author":"Fu","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0154","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1111\/j.1600-6143.2005.01113.x","article-title":"HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jcv.2004.10.006","article-title":"HBV reactivation after kidney transplantation","volume":"32","author":"Berger","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1016\/j.dld.2025.10.025_bib0156","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1053-2498(01)00255-8","article-title":"HBV and HCV infections in heart transplant recipients","volume":"20","author":"Fagiuoli","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0157","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/01.tp.0000176941.21438.95","article-title":"Heart transplantation in patients with chronic hepatitis B: clinical evaluation, molecular analysis and effect of treatment","volume":"80","author":"Zampino","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0158","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jhep.2022.03.007","article-title":"HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist","volume":"77","author":"Russo","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0159","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.dld.2016.12.027","article-title":"Common issues in the management of patients in the waiting list and after liver transplantation","volume":"49","author":"Burra","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0160","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/apt.16374","article-title":"2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation","volume":"54","author":"Duvoux","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0161","article-title":"Liver transplantation for HBV-related liver disease: impact of prophylaxis for HBV on HCC recurrence","volume":"7","author":"Burra","year":"2024","journal-title":"J HEP Rep"},{"key":"10.1016\/j.dld.2025.10.025_bib0162","unstructured":"https:\/\/www.trapianti.salute.gov.it"},{"key":"10.1016\/j.dld.2025.10.025_bib0163","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1053\/ajkd.2001.28607","article-title":"Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients","volume":"38","author":"Lee","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0164","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91331-y","article-title":"Outcome after kidney transplantation in hepatitis B surface antigen-positive patients","volume":"11","author":"Mo","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.dld.2025.10.025_bib0165","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ekir.2023.05.005","article-title":"Hepatitis B virus reactivation in kidney transplant recipients treated with belatacept","volume":"8","author":"Schwarz","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.dld.2025.10.025_bib0166","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jss.2022.10.078","article-title":"Hepatitis B in heart transplant donors and recipients: a systematic review and meta-analysis","volume":"283","author":"Yost","year":"2023","journal-title":"J Surg Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0167","doi-asserted-by":"crossref","first-page":"182","DOI":"10.12659\/AOT.889680","article-title":"The impact of hepatitis B on heart transplantation: 19 years of national experience in Korea","volume":"19","author":"Shin","year":"2014","journal-title":"Ann Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0168","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcv.2017.09.011","article-title":"Hepatitis B virus reactivation after heart transplant: incidence and clinical impact","volume":"96","author":"Vitrone","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.dld.2025.10.025_bib0169","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1053-2498(01)00280-7","article-title":"Hepatitis B virus infection in heart transplant recipients in a hepatitis B endemic area","volume":"20","author":"Ko","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0170","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.cmi.2017.06.024","article-title":"Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review","volume":"23","author":"Gentile","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.dld.2025.10.025_bib0171","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V96.2.452.014k13_452_458","article-title":"A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation","volume":"96","author":"Lau","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.10.025_bib0172","doi-asserted-by":"crossref","DOI":"10.1053\/jhep.2002.35068","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoieticcell transplantation","volume":"36","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0173","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-6143.2005.00887.x","article-title":"Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors","volume":"5","author":"Hui","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0174","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-021-04730-6","article-title":"Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area","volume":"101","author":"Wu","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0175","doi-asserted-by":"crossref","DOI":"10.1038\/bmt.2015.328","article-title":"A comparison of lamivudine vs. entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single institutional experience","volume":"51","author":"Shang","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0176","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12072-016-9747-0","article-title":"HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea","volume":"11","author":"Jun","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0177","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s00277-020-04206-z","article-title":"Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country","volume":"99","author":"Murt","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0178","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbmt.2009.12.533","article-title":"Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation","volume":"16","author":"Giaccone","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0179","doi-asserted-by":"crossref","first-page":"21455","DOI":"10.3390\/ijms151121455","article-title":"Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment","volume":"15","author":"Nakamoto","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dld.2025.10.025_bib0180","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.bbmt.2018.02.027","article-title":"Prophylaxis for Hepatitis B Virus reactivation after allogeneic stem cell transplantation in the era of drug resistance and newer antivirals: a systematic review and meta-analysis","volume":"24","author":"Siyahian","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0181","article-title":"High risk of hepatitis B reactivation among patients with acute myeloid leukemia","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2025.10.025_bib0182","doi-asserted-by":"crossref","DOI":"10.1517\/14656560903251710","article-title":"Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin\u2019s lymphoma: single institution experience","volume":"10","author":"Huang","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.dld.2025.10.025_bib0183","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.3390\/ijms22179116","article-title":"High risk of viral reactivation in Hepatitis B patients with systemic Lupus Erythematosus","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dld.2025.10.025_bib0184","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.3390\/jcm10153296","article-title":"Long-term safety in HBsAg-negative, HBcAb-positive patients with rheumatic diseases receiving maintained steroid therapy after pulse therapy","volume":"10","author":"Lin","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jhep.2019.08.023","article-title":"Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure","volume":"72","author":"Wong","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0186","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.71","article-title":"Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency","volume":"2","author":"Hatano","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.dld.2025.10.025_bib0187","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/annrheumdis-2021-221650","article-title":"Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection","volume":"81","author":"Zhong","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0188","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-014-0033-1","article-title":"Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series","volume":"2","author":"Ravi","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0189","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.21037\/tlcr-21-455","article-title":"Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1\/PD-L1 therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0190","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jgh3.12737","article-title":"Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection","volume":"6","author":"Nakabori","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.dld.2025.10.025_bib0191","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.916213","article-title":"The low incidence of viral Hepatitis reactivation among subjects on immunotherapy reduces the impact of suboptimal screening rate","volume":"9","author":"Aceituno","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0192","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1044098","article-title":"Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: a real-life retrospective single-center cohort study","volume":"13","author":"Lasagna","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0193","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0194","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejim.2010.04.010","article-title":"Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients","volume":"21","author":"Watanabe","year":"2010","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0609.2010.01474.x","article-title":"Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative\/HBcAb-positive: a multicenter retrospective study","volume":"85","author":"Ji","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0196","first-page":"376","article-title":"Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy","volume":"17","author":"Cheung","year":"2011","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.dld.2025.10.025_bib0197","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000343056","article-title":"Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers","volume":"30","author":"Hagiwara","year":"2012","journal-title":"Dig Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0198","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-230X-14-31","article-title":"Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma","volume":"14","author":"Masarone","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0199","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jnci.2015.01.004","article-title":"Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening","volume":"27","author":"Elbedewy","year":"2015","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.dld.2025.10.025_bib0200","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5604\/16652681.1231579","article-title":"Viral outcome in patients with occult HBV infection or HCV-ab positivity treated for lymphoma","volume":"16","author":"Guarino","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0201","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10147-020-01814-7","article-title":"Hepatitis B virus reactivation during temozolomide administration for malignant glioma","volume":"26","author":"Shoji","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0202","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.cgh.2018.04.033","article-title":"Incidence of Hepatitis B Virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists","volume":"16","author":"Pauly","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0203","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases","volume":"62","author":"Caporali","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0204","first-page":"285","article-title":"Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease","volume":"25","author":"Cassano","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.dld.2025.10.025_bib0205","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"Mori","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0206","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00535-010-0367-5","article-title":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts","volume":"46","author":"Tamori","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0207","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.crohns.2012.03.001","article-title":"Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-\u03b1 agents","volume":"7","author":"Papa","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.10.025_bib0208","first-page":"25","article-title":"No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study","volume":"31","author":"Giardina","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.dld.2025.10.025_bib0209","first-page":"S42","article-title":"Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients","volume":"75","author":"Ballanti","year":"2014","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0210","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/ijd.12313","article-title":"Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis","volume":"5","author":"Navarro","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0211","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejim.2013.11.014","article-title":"Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies","volume":"25","author":"Biondo","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0212","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","author":"Barone","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0213","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"Nakamura","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0214","first-page":"93","article-title":"Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study","volume":"35","author":"Giannitti","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0215","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/jdv.14146","article-title":"Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature","volume":"31","author":"Piaserico","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.dld.2025.10.025_bib0216","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2018.03.013","article-title":"Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation","volume":"191","author":"Clarke","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.dld.2025.10.025_bib0217","first-page":"102","article-title":"Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study","volume":"36","author":"Papalopoulos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0218","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar2868","article-title":"Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients","volume":"11","author":"Charpin","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0219","doi-asserted-by":"crossref","first-page":"522","DOI":"10.5152\/tjg.2020.19295","article-title":"Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection","volume":"31","author":"Sayar","year":"2020","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0220","doi-asserted-by":"crossref","first-page":"428","DOI":"10.5114\/ada.2020.96910","article-title":"Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study)","volume":"37","author":"Narcisi","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.dld.2025.10.025_bib0221","doi-asserted-by":"crossref","first-page":"294","DOI":"10.5152\/tjg.2021.201131","article-title":"What is the risk of reactivation in patients with resolved and past HBV infection during immunosuppressive therapy if HBV-DNA negative before treatment?","volume":"32","author":"Tokmak","year":"2021","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0222","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/1756-185X.14034","article-title":"Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-\u03b1 therapy","volume":"24","author":"Fidan","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0223","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5009\/gnl210081","article-title":"Clinical course of Hepatitis B viral infection in patients undergoing anti-tumor necrosis factor \u03b1 therapy for inflammatory bowel disease","volume":"16","author":"Lee","year":"2022","journal-title":"Gut Liver"},{"key":"10.1016\/j.dld.2025.10.025_bib0224","first-page":"424","article-title":"Occult HBV reactivation induced by ibrutinib treatment: a case report","volume":"78","author":"de J\u00e9sus Ngoma","year":"2015","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.dld.2025.10.025_bib0225","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12185-015-1788-y","article-title":"Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia","volume":"102","author":"Ando","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0226","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1080\/10428194.2017.1317094","article-title":"Is HBV prophylaxis required during CLL treatment with ibrutinib?","volume":"58","author":"Tedeschi","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0227","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/10428194.2016.1219906","article-title":"Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"58","author":"Sor\u00e0","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0228","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","article-title":"Risk of hepatitis B virus reactivation in patients treated with ibrutinib","volume":"131","author":"Hammond","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.10.025_bib0229","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1080\/10428194.2018.1523401","article-title":"HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis","volume":"60","author":"Innocenti","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0230","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.clml.2019.12.006","article-title":"Hepatitis B virus-associated liver failure in a patient with B-cell non-hodgkin lymphoma after anti-cancer therapy including Ibrutinib","volume":"20","author":"Malek","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.dld.2025.10.025_bib0231","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/hepr.13575","article-title":"Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course","volume":"51","author":"Tsuruya","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0232","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000518398","article-title":"Ibrutinib in advanced chronic lymphocytic leukemia\/small lymphocytic lymphoma: lower risk of Hepatitis B virus reactivation","volume":"145","author":"Yang","year":"2022","journal-title":"Acta Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0233","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.982346","article-title":"Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy","volume":"13","author":"Ni","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.dld.2025.10.025_bib0234","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2021.280325","article-title":"Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study","volume":"107","author":"Innocenti","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.dld.2025.10.025_bib0235","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1159\/000516747","article-title":"Chronic myeloid leukemia in a patient with Hepatitis B virus infection: a case report","volume":"14","author":"Ali Hailan","year":"2021","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0236","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clml.2023.04.006","article-title":"Hepatitis B virus reactivation in patients receiving bruton tyrosine kinase inhibitors","volume":"23","author":"Chiu","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.dld.2025.10.025_bib0237","first-page":"43","article-title":"Hepatitis B virus reactivation after ibrutinib treatment","volume":"116","author":"MateuC","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.dld.2025.10.025_bib0238","doi-asserted-by":"crossref","first-page":"704","DOI":"10.4143\/crt.2022.1524","article-title":"Won YW. Hepatitis B virus reactivation in a chronic lymphocytic leukemia patient treated with Ibrutinib","volume":"55","author":"Choi","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.dld.2025.10.025_bib0239","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejca.2020.02.026","article-title":"Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection","volume":"130","author":"Lee","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0240","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/jcm12010231","article-title":"Reactivation of Hepatitis B virus in lung cancer patients receiving tyrosine kinase inhibitor treatment","volume":"12","author":"Lee","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0241","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2169\/internalmedicine.2731-23","article-title":"De novo Hepatitis B virus reactivation during treatment with an epidermal growth factor receptor tyrosine kinase inhibitor in a patient with advanced lung cancer: a case report","volume":"63","author":"Horibe","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0242","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001095","article-title":"Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis","volume":"6","author":"Harigai","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.dld.2025.10.025_bib0243","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0244","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/annrheumdis-2020-218289","article-title":"The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series","volume":"80","author":"Serling-Boyd","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0245","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.dld.2017.03.004","article-title":"Occult hepatitis B infection reactivation after ruxolitinib therapy","volume":"49","author":"Perricone","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0246","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00277-018-3405-7","article-title":"Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment","volume":"98","author":"Gill","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0247","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/16078454.2021.1945234","article-title":"Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms","volume":"26","author":"Duan","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.dld.2025.10.025_bib0248","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10428194.2020.1832671","article-title":"Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib","volume":"62","author":"Garcia-Horton","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0249","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00277-022-04851-6","article-title":"Hepatitis B reactivation during ruxolitinib treatment","volume":"101","author":"Sjoblom","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0250","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1163175","article-title":"Case Report: infectious prophylaxis in hematological malignancies","volume":"13","author":"Passucci","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0251","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3349\/ymj.2018.59.3.452","article-title":"Safety of Tocilizumab in rheumatoid arthritis patients with resolved Hepatitis B virus infection: data from real-world experience","volume":"59","author":"Ahn","year":"2018","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.dld.2025.10.025_bib0252","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jvh.13410","article-title":"Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy","volume":"28","author":"Rodr\u00edguez-Tajes","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0253","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15274","article-title":"Safety of therapies using ustekinumab in patients with psoriasis who have had hepatitis B virus infection","volume":"35","author":"K\u0142ujszo","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0254","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s13555-022-00726-w","article-title":"Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral Hepatitis: a monocentric retrospective study","volume":"12","author":"Gargiulo","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0255","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12601","article-title":"Secukinumab: a positive outcome in a patient with severe psoriasis and HBV-HCV co-infection","volume":"31","author":"Peccerillo","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0256","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1684\/ejd.2022.4263","article-title":"Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study. Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study","volume":"32","author":"Qin","year":"2022","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0257","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40261-022-01163-5","article-title":"Hepatitis virus reactivation in patients with Psoriasis treated with Secukinumab in a real-world setting of Hepatitis B or Hepatitis C infection","volume":"42","author":"Megna","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.dld.2025.10.025_bib0258","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cia2.12209","article-title":"Dupilumab in atopic dermatitis patients with chronic hepatitis B","volume":"5","author":"Matsutani","year":"2022","journal-title":"J Cutan Immunol Allergy"},{"key":"10.1016\/j.dld.2025.10.025_bib0259","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12909","article-title":"Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection","volume":"32","author":"Lora","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0260","article-title":"Mepolizumab in allergic bronchopulmonary aspergillosis complicated by infection","volume":"45","author":"Hamada","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.dld.2025.10.025_bib0261","doi-asserted-by":"crossref","DOI":"10.5070\/D32510045827","article-title":"Safety of guselkumab in hepatitis B virus infection","volume":"25","author":"Duncan","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.dld.2025.10.025_bib0262","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/liv.15793","article-title":"HBV reactivation in HBsAg-\/HBcAb+ rheumatoid arthritis patients receiving biologic\/targeted synthetic DMARDs","volume":"44","author":"Kuo","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0263","doi-asserted-by":"crossref","first-page":"546","DOI":"10.55563\/clinexprheumatol\/c25fja","article-title":"Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy","volume":"39","author":"Ditto","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0264","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.cgh.2020.03.039","article-title":"Low but long-lasting risk of reversal of seroconversion in patients with rheumatoid arthritis receiving immunosuppressive therapy","volume":"18","author":"Chen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1620\/tjem.252.133","article-title":"Multidisciplinary approach to prevent de novo Hepatitis B in patients with rheumatoid arthritis","volume":"252","author":"Watanabe","year":"2020","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0266","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-019-2053-1","article-title":"Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital","volume":"21","author":"Fukuda","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.dld.2025.10.025_bib0267","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10067-018-4295-8","article-title":"Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients","volume":"37","author":"Schwaneck","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0268","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jvh.12933","article-title":"Hepatitis B virus reactivation in patients with rheumatoid arthritis: analysis of the National Database of Japan","volume":"25","author":"Fujita","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0269","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2169\/internalmedicine.55.5425","article-title":"Hepatitis B virus reactivation following salazosulfapyridine monotherapy in a patient with rheumatoid arthritis","volume":"55","author":"Akashi","year":"2016","journal-title":"Intern Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0270","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12072-014-9597-6","article-title":"Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients","volume":"9","author":"Laohapand","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0271","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-012-1988-2","article-title":"Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs","volume":"31","author":"Tan","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0272","first-page":"888","article-title":"Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate","volume":"25","author":"Gwak","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0273","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/964082","article-title":"Bortezomib induced hepatitis B reactivation","author":"Hussain","year":"2014","journal-title":"Case Rep Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0274","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3960\/jslrt.52.67","article-title":"Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report","volume":"52","author":"Tanaka","year":"2012","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.dld.2025.10.025_bib0275","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00277-023-05090-z","article-title":"Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA","volume":"102","author":"Suzuki","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0276","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/ajg.2016.436","article-title":"Association of Hepatitis B core-related antigen with Hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy","volume":"111","author":"Seto","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0277","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2018.02.033","article-title":"Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection","volume":"69","author":"Yang","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0278","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.19140","article-title":"Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients","volume":"203","author":"Liu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0279","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.3346\/jkms.2023.38.e216","article-title":"Efficacy of antiviral prophylaxis up to 6 or 12 months from completion of Rituximab in resolved Hepatitis B patients: a multicenter, randomized study","volume":"38","author":"Jang","year":"2023","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.dld.2025.10.025_bib0280","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28549","article-title":"HBsAg (-)\/HBsAb (-)\/HBeAg (-)\/HBeAb (+)\/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy","volume":"95","author":"Shui","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.dld.2025.10.025_bib0281","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/jpm12020285","article-title":"HBV reactivation in patients with past infection affected by non-hodgkin lymphoma and treated with anti-CD20 antibody based immuno-chemotherapy: a multicenter experience","volume":"12","author":"Clerico","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0282","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1080\/10428194.2021.1948034","article-title":"Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab","volume":"62","author":"Pei","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0283","doi-asserted-by":"crossref","first-page":"e7481","DOI":"10.7717\/peerj.7481","article-title":"Rituximab increases the risk of hepatitis B virus reactivation in non-hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study","volume":"7","author":"Tsai","year":"2019","journal-title":"Peer J"},{"key":"10.1016\/j.dld.2025.10.025_bib0284","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s10620-019-05614-6","article-title":"Early Hepatitis B surface antigen seroclearance following antiviral treatment in patients with reactivation of resolved Hepatitis B","volume":"64","author":"Lee","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2025.10.025_bib0285","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3904\/kjim.2018.196","article-title":"Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0286","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s15010-019-01271-z","article-title":"HBsAg-negative\/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?","volume":"47","author":"Dr\u00f6\u00dfler","year":"2019","journal-title":"Infection"},{"key":"10.1016\/j.dld.2025.10.025_bib0287","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13027-018-0215-4","article-title":"Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome","volume":"13","author":"Guo","year":"2018","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0288","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41409-018-0355-6","article-title":"HBV reactivation after hematopoietic stem cell transplantation and rituximab-containing chemotherapy: a 12-year experience at a single center","volume":"54","author":"Bae","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0289","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.cgh.2018.09.020","article-title":"Monitoring and treatment of patients undergoing immunotherapy with anti-CD20 who are exposed to HBV","volume":"17","author":"Seto","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0290","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.4103\/0366-6999.237401","volume":"131","author":"Wu","year":"2018","journal-title":"Chin Med J"},{"key":"10.1016\/j.dld.2025.10.025_bib0291","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/MEG.0000000000001130","article-title":"Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy","volume":"30","author":"Su","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0292","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184550","article-title":"Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study","volume":"12","author":"Buti","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2025.10.025_bib0293","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12072-017-9817-y","article-title":"Risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis","volume":"11","author":"Tang","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0294","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.dld.2016.08.113","article-title":"High rate of hepatitis B viral breakthrough in elderly non-hodgkin lymphomas patients treated with Rituximab based chemotherapy","volume":"48","author":"Castelli","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0295","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MEG.0000000000000749","article-title":"Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience","volume":"29","author":"Papadopoulos","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0296","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/s12885-016-2523-7","article-title":"Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study","volume":"16","author":"Wu","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0297","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jmv.24423","article-title":"High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma","volume":"88","author":"Cho","year":"2016","journal-title":"J Med Virol"},{"key":"10.1016\/j.dld.2025.10.025_bib0298","doi-asserted-by":"crossref","first-page":"e1321","DOI":"10.1097\/MD.0000000000001321","article-title":"Risk of reverse seroconversion of Hepatitis B virus surface antigen in Rituximab-treated non-hodgkin lymphoma patients: a large cohort retrospective study","volume":"94","author":"Hsiao","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.dld.2025.10.025_bib0299","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s40880-015-0015-9","article-title":"Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival","volume":"34","author":"Chen","year":"2015","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0300","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0301","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3109\/10428194.2014.991922","article-title":"Lymphocyte\/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B","volume":"56","author":"Wu","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0302","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3109\/10428194.2014.947606","article-title":"The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy","volume":"56","author":"Lu","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0303","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/jgh.12604","article-title":"Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy","volume":"29","author":"Tamori","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0304","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0305","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/jmv.23694","article-title":"Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma","volume":"85","author":"Matsui","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.dld.2025.10.025_bib0306","first-page":"91","article-title":"Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab","volume":"17","author":"Gigi","year":"2013","journal-title":"Hippokratia"},{"key":"10.1016\/j.dld.2025.10.025_bib0307","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00277-011-1241-0","article-title":"Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis","volume":"90","author":"Koo","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0308","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1478-3231.2010.02417.x","article-title":"Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection","volume":"31","author":"Watanabe","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0309","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1002\/cncr.25253","article-title":"Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma","volume":"116","author":"Matsue","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0310","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s15010-009-9019-1","article-title":"Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy","volume":"38","author":"Francisci","year":"2010","journal-title":"Infection"},{"key":"10.1016\/j.dld.2025.10.025_bib0311","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1093\/annonc\/mdp230","article-title":"Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier","volume":"20","author":"Fukushima","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0312","unstructured":"http:\/\/wayback.archiveit.org\/7993\/20170113093146\/http:\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM369436.pdf"},{"key":"10.1016\/j.dld.2025.10.025_bib0313","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1002\/iid3.780","article-title":"Risk of hepatitis B reactivation in HBsAg-\/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: a meta-analysis","volume":"11","author":"Hong","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0314","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5009\/gnl210551","article-title":"Risk of Hepatitis B Virus (HBV) reactivation in HBsAg-negative, anti-HBc-negative patients receiving Rituximab for autoimmune diseases in HBV endemic areas","volume":"17","author":"Lan","year":"2023","journal-title":"Gut Liver"},{"key":"10.1016\/j.dld.2025.10.025_bib0315","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/MEG.0000000000001132","article-title":"Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases","volume":"30","author":"Spinicci","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0316","first-page":"831","article-title":"Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis","volume":"35","author":"Tien","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0317","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3899\/jrheum.151105","article-title":"Low risk of Hepatitis B virus reactivation in HBsAg-negative\/anti-HBc-positive carriers receiving Rituximab for rheumatoid arthritis: a retrospective multicenter Italian study","volume":"43","author":"Varisco","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0318","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00415-023-11973-y","article-title":"Hepatitis B reactivation is a rare event among patients with resolved infection undergoing anti-CD20 antibodies in monotherapy without antiviral prophylaxis: results from the HEBEM study","volume":"271","author":"Marzo","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.dld.2025.10.025_bib0319","doi-asserted-by":"crossref","first-page":"189","DOI":"10.36740\/Merkur202303101","article-title":"Ocrelizumab therapy In patients with anti-Hbc antibodies - a preliminary study","volume":"51","author":"Niedziela","year":"2023","journal-title":"Pol Merkur Lekarski"},{"key":"10.1016\/j.dld.2025.10.025_bib0320","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00415-022-11009-x","article-title":"Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study","volume":"269","author":"Buonomo","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.dld.2025.10.025_bib0321","doi-asserted-by":"crossref","first-page":"ofy356","DOI":"10.1093\/ofid\/ofy356","article-title":"Reactivation of Hepatitis B virus with immune-escape mutations after Ocrelizumab treatment for multiple sclerosis","volume":"6","author":"Ciardi","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0322","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3960\/jslrt.19034","article-title":"Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy","volume":"60","author":"Kikuchi","year":"2020","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.dld.2025.10.025_bib0323","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/jmv.20705","article-title":"Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab","volume":"78","author":"Moses","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.dld.2025.10.025_bib0324","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0609.2004.00375.x","article-title":"Hepatitis B virus reactivation and alemtuzumab therapy","volume":"74","author":"Iannitto","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0325","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/19418744231171464","article-title":"Neuromyelitis Optica Spectrum Disorder management in the setting of chronic Hepatitis B and latent tuberculosis: a case report","volume":"13","author":"Sadowsky","year":"2023","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.dld.2025.10.025_bib0326","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11122","article-title":"Risk stratification for Hepatitis B virus reactivation in kidney transplant recipients with resolved HBV infection","volume":"36","author":"Tsai","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0327","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004196","article-title":"Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: a systematic review and meta-analysis","volume":"20","author":"Yin","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0328","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12985-022-01946-4","article-title":"Reactivation of occult hepatitis B virus infection in a renal transplant recipient","volume":"19","author":"Jiang","year":"2022","journal-title":"Virol J"},{"key":"10.1016\/j.dld.2025.10.025_bib0329","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13751","article-title":"A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation","volume":"24","author":"Shaikh","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0330","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019407","article-title":"Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients","volume":"99","author":"\u00c1lvarez-L\u00f3pez","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.dld.2025.10.025_bib0331","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/jvh.13279","article-title":"Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients","volume":"27","author":"Kim","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0332","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13234","article-title":"Hepatitis B virus reactivation in kidney transplant patients with resolved hepatitis B virus infection: risk factors and the safety and efficacy of preemptive therapy","volume":"22","author":"Mei","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0333","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13170","article-title":"Hepatitis B virus reactivation during belatacept treatment after kidney transplantation","volume":"21","author":"Cambier","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0334","article-title":"Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.dld.2025.10.025_bib0335","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13009","article-title":"Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients","volume":"21","author":"Querido","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0336","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.nefroe.2018.02.013","article-title":"Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: a single-center experience","volume":"38","author":"Meng","year":"2018","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.dld.2025.10.025_bib0337","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/TP.0000000000002173","article-title":"Presence of Hepatitis B surface antibody in addition to Hepatitis B core antibody confers protection against Hepatitis B virus infection in Hepatitis B surface antigen-negative patients undergoing kidney transplantation","volume":"102","author":"Jeon","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0338","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/TP.0000000000001870","article-title":"Incidence of Hepatitis B viral reactivation after kidney transplantation with low-dose rituximab administration","volume":"102","author":"Masutani","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0339","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/ndt\/gfw455","article-title":"Rituximab and hepatitis B reactivation in HBsAg-negative\/anti-HBc-positive kidney transplant recipients","volume":"32","author":"Lee","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0340","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.transproceed.2013.01.093","article-title":"Clinical and virologic courses of hepatitis B surface antigen-negative and hepatitis B core or hepatitis B surface antibody-positive renal transplant recipients","volume":"45","author":"Nishimura","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2025.10.025_bib0341","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/tid.12065","article-title":"Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers","volume":"15","author":"Chen","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0342","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jcv.2012.07.015","article-title":"Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection","volume":"55","author":"Kanaan","year":"2012","journal-title":"J Clin Virol"},{"key":"10.1016\/j.dld.2025.10.025_bib0343","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/01.TP.0000163468.80223.74","article-title":"Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation","volume":"79","author":"Kn\u00f6ll","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0344","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1034\/j.1399-3062.2003.00021.x","article-title":"Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation","volume":"5","author":"Duhart","year":"2003","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0345","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/00007890-199810150-00012","article-title":"Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature","volume":"66","author":"Blanpain","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0346","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13436","article-title":"Self-limited HBV infection of the recipient does not reactivate after liver transplantation: observations from a 30-year liver transplant program","volume":"23","author":"Ossami Saidy","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0347","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/vaccines11101611","article-title":"Vaccination recommendations in solid organ transplant adult candidates and recipients","volume":"11","author":"Vigan\u00f2","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.dld.2025.10.025_bib0348","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/jvh.13740","article-title":"Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection","volume":"29","author":"Yamada","year":"2022","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0349","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.transproceed.2014.06.067","article-title":"Safety of kidney transplantation using anti-HBc-positive donors","volume":"46","author":"Abr\u00e3o","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2025.10.025_bib0350","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1399-3062.2012.00782.x","article-title":"Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature","volume":"14","author":"Mahboobi","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0351","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.tp.0000189930.89031.1b","article-title":"Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study","volume":"81","author":"De Feo","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0352","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1016\/j.transproceed.2005.06.068","article-title":"Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and -negative recipients","volume":"37","author":"Veroux","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2025.10.025_bib0353","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.transproceed.2004.12.041","article-title":"Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study","volume":"37","author":"De Feo","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2025.10.025_bib0354","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/00007890-199712270-00027","article-title":"Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease","volume":"64","author":"Madayag","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0355","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1016\/j.transproceed.2005.11.025","article-title":"Frequent detection of hepatitis B core antibodies in heart transplant recipients without preceding hepatitis B infection","volume":"37","author":"Tenderich","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2025.10.025_bib0356","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00007890-199501270-00014","article-title":"The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors","volume":"59","author":"Wachs","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0357","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000165858.86067.a2","article-title":"Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation","volume":"80","author":"Hartwig","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0358","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3350\/cmh.2021.0137","article-title":"Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0359","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.07.003","article-title":"HBV-infection rate and long-term outcome after liver-transplantation of anti-HBc-positive liver-grafts to HBV-na\u00efve recipients: a retrospective study","volume":"45","author":"Hornuss","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0360","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jceh.2020.05.001","article-title":"Hepatitis B reactivation in liver transplant recipients with Hepatitis B virus core antibody positive grafts: a retrospective study","volume":"10","author":"Khiangte","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0361","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2019.03.003","article-title":"Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis","volume":"70","author":"Wong","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0362","first-page":"1","article-title":"Prevalent use of combined prophylaxis of hepatitis B after liver transplantation in Italy: results of a national survey in a large cohort","volume":"64","author":"Marzano","year":"2018","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.dld.2025.10.025_bib0363","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S1590-8658(24)00360-8","article-title":"Long-term high-risk of de-novo HBV-Hepatitis (DNHB) in HBsAg-negative liver transplant recipients of anti-HBc positive graft: a multicentre real-life experience","volume":"56","author":"Dondossola","year":"2024","journal-title":"Digestive Liver Disease"},{"key":"10.1016\/j.dld.2025.10.025_bib0364","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/lt.24814","article-title":"Active immunization for prevention of de novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft","volume":"23","author":"Wang","year":"2017","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2025.10.025_bib0365","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/tri.12741","article-title":"Inferior graft survival of hepatitis B core positive grafts is not influenced by post-transplant hepatitis B infection in liver recipients\u20135-year single-center experience","volume":"29","author":"Brandl","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0366","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.transproceed.2013.07.049","article-title":"Use of grafts from anti-HBc-positive donors in liver transplantation: a 5-year, single-center experience","volume":"45","author":"Bortoluzzi","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2025.10.025_bib0367","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/lt.22084","article-title":"Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins","volume":"16","author":"Roche","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2025.10.025_bib0368","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2009.11.009","article-title":"Liver grafts from anti-hepatitis B core positive donors: a systematic review","volume":"52","author":"Cholongitas","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.10.025_bib0369","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.3748\/wjg.v12.i13.2070","article-title":"Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers","volume":"12","author":"Barcena","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0370","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1034\/j.1399-0012.2002.01133.x","article-title":"Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors","volume":"16","author":"Chen","year":"2002","journal-title":"Clin Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0371","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1053\/jlts.2002.35555","article-title":"Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation","volume":"8","author":"Castells","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2025.10.025_bib0372","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/gut.50.1.95","article-title":"Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors","volume":"50","author":"Roque-Afonso","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.dld.2025.10.025_bib0373","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/jlts.2001.20786","article-title":"De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population","volume":"7","author":"Prieto","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2025.10.025_bib0374","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1053\/gast.1997.v113.pm9352871","article-title":"Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database","volume":"113","author":"Dickson","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.10.025_bib0375","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/lt.500030202","article-title":"The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient","volume":"3","author":"Douglas","year":"1997","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.dld.2025.10.025_bib0376","first-page":"1268","article-title":"Use of livers from hepatitis B core antibody positive donors in living donor liver transplantation","volume":"57","author":"Yaprak","year":"2010","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.dld.2025.10.025_bib0377","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12072-010-9188-0","article-title":"Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers","volume":"4","author":"Chotiyaputta","year":"2010","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0378","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.transproceed.2006.11.015","article-title":"Living donor liver transplantation from hepatitis B core antibody positive donors","volume":"39","author":"Celebi Kobak","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.dld.2025.10.025_bib0379","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.lts.2003.09.010","article-title":"Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?","volume":"9","author":"Jr","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2025.10.025_bib0380","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/01.TP.0000065283.98275.FE","article-title":"Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine","volume":"75","author":"Nery","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0381","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archsurg.137.5.572","article-title":"Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation","volume":"137","author":"Holt","year":"2002","journal-title":"Arch Surg"},{"key":"10.1016\/j.dld.2025.10.025_bib0382","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/jlts.2001.23911","article-title":"Transmission of hepatitis B infection from hepatitis B core antibody\u2013positive liver allografts is prevented by lamivudine therapy","volume":"7","author":"Yu","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2025.10.025_bib0383","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/00007890-199910150-00028","article-title":"Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors","volume":"68","author":"Dodson","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.dld.2025.10.025_bib0384","doi-asserted-by":"crossref","first-page":"O694","DOI":"10.1111\/1469-0691.12611","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome","volume":"20","author":"Mikulska","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.dld.2025.10.025_bib0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104765","article-title":"Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients","volume":"177","author":"Wu","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0386","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2020.01.006","article-title":"Determining whether prophylactic antiviral treatment is necessary in HBsAg-negative\/HBcAb-positive patients receiving allogeneic hematopoietic stem cell transplantation","volume":"26","author":"Zhang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0387","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.15884","article-title":"Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study","volume":"186","author":"Liu","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0388","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1111\/liv.12882","article-title":"Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation","volume":"35","author":"Yoo","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0389","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/bmt.2010.70","article-title":"Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT","volume":"46","author":"Vigan\u00f2","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0390","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.bbmt.2009.12.532","article-title":"Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Ramos","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0391","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2893.2009.01239.x","article-title":"Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and\/or autologous stem cell transplantation for cancer","volume":"17","author":"Borentain","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0392","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/sj.bmt.1704457","article-title":"Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation","volume":"33","author":"Kn\u00f6ll","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.dld.2025.10.025_bib0393","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2016.07.021","article-title":"Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor","volume":"22","author":"Cerva","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.dld.2025.10.025_bib0394","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.trim.2004.10.001","article-title":"Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation","volume":"13","author":"Zekri","year":"2004","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.dld.2025.10.025_bib0395","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2014.15704","article-title":"Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial","volume":"312","author":"Huang","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2025.10.025_bib0396","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10549-011-1455-9","article-title":"A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?","volume":"127","author":"Long","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.dld.2025.10.025_bib0397","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12072-015-9612-6","article-title":"Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy","volume":"9","author":"Ho","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0398","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V100.2.391","article-title":"Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers","volume":"100","author":"Shibolet","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.10.025_bib0399","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1365-2893.2003.00479.x","article-title":"Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies","volume":"11","author":"Idilman","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0400","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.29022","article-title":"Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study","volume":"65","author":"Seto","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0401","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study group for infections in compromised hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.dld.2025.10.025_bib0402","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.10.025_bib0403","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.685706","article-title":"HBV reactivation during the treatment of non-Hodgkin Lymphoma and management strategies","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2025.10.025_bib0404","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10096-023-04685-8","article-title":"Late HBV reactivation after hematopoietic stem cell transplantation, despite long-term prophylaxis","volume":"42","author":"Viscovo","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2022.e01393","article-title":"Late Hepatitis B reactivation after treatment with rituximab","volume":"27","author":"Pereira","year":"2022","journal-title":"IDCases"},{"key":"10.1016\/j.dld.2025.10.025_bib0406","doi-asserted-by":"crossref","unstructured":"Ciccullo A., Ponziani F.R., Maiolo E., et al. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report Infection. 2019;47:313\u20136.","DOI":"10.1007\/s15010-018-1242-1"},{"key":"10.1016\/j.dld.2025.10.025_bib0407","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jinf.2011.11.021","article-title":"Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy","volume":"65","author":"Ceccarelli","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.dld.2025.10.025_bib0408","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1399-3062.2011.00659.x","article-title":"Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy","volume":"14","author":"Milazzo","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.dld.2025.10.025_bib0409","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2015.1116121","article-title":"Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma","volume":"57","author":"Liu","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0410","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.leukres.2016.09.014","article-title":"Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA?","volume":"50","author":"Nakaya","year":"2016","journal-title":"Leuk Res"},{"key":"10.1016\/j.dld.2025.10.025_bib0411","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3109\/10428194.2014.947978","article-title":"Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen","volume":"56","author":"Dominguez","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.dld.2025.10.025_bib0412","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ajh.21214","article-title":"Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?","volume":"83","author":"Garcia-Rodriguez","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.dld.2025.10.025_bib0413","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.3324\/haematol.2017.168609","article-title":"Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports","volume":"102","author":"Grossi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.dld.2025.10.025_bib0414","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0415","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12876-014-0214-x","article-title":"Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis","volume":"14","author":"Morisco","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.dld.2025.10.025_bib0416","doi-asserted-by":"crossref","first-page":"7365","DOI":"10.1038\/s41598-022-10665-3","article-title":"Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-hodgkin lymphoma","volume":"12","author":"Fujita","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.dld.2025.10.025_bib0417","article-title":"A comparison of Entecavir and Lamivudine for the prophylaxis of Hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2025.10.025_bib0418","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/liv.12154","article-title":"Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease","volume":"33","author":"Chen","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.10.025_bib0419","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2893.2010.01386.x","article-title":"Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy","volume":"18","author":"Li","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.10.025_bib0420","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.10.025_bib0421","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/blood-2018-10-878892","article-title":"Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL","volume":"133","author":"Picardi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.dld.2025.10.025_bib0422","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s10620-020-06506-w","article-title":"Comparison of Tenofovir disoproxil fumarate and entecavir in the prophylaxis of HBV reactivation","volume":"66","author":"Toka","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2025.10.025_bib0423","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jgh3.12636","article-title":"Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis","volume":"5","author":"Inada","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.dld.2025.10.025_bib0424","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.10.025_bib0425","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000525499","article-title":"Hepatic events and viral kinetics in hepatocellular carcinoma patients treated with Atezolizumab plus Bevacizumab","volume":"12","author":"Hsu","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.dld.2025.10.025_bib0426","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825011843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825011843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:23:02Z","timestamp":1766154182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825011843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":426,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1590865825011843"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.10.025","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Societ\u00e0 Italiana di Reumatologia (SIR), Societ\u00e0 Italiana Trapianti d'Organo (SITO), Societ\u00e0 Italiana di Gastroenterologia (SIGE), Societ\u00e0 Italiana di Malattie Infettive e Tropicali (SIMIT)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}